Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute — Boston, Massachusetts

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 85/100 (GOOD). This profile has not yet been claimed by the site owner.

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute has participated in 41 clinical trials with 4 currently active.

Therapeutic areas: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma.

Sponsors: Tufts Medical Center, ETOP IBCSG Partners Foundation, Alliance for Clinical Trials in Oncology.

Sponsor Feasibility Report

Trust Score: 85/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute?

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute has a Crixeo Trust Score of 85/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute conducted?

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute has 41 clinical trials on record, with 4 currently active. Their work covers Chronic Myeloproliferative Disorders, Leukemia, Lymphoma.

Is Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute accredited by Crixeo Health?

Yes — Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.